Search

everythinglearnresearchcommunity

for

Search:↓

A user's 1 year progress of using finasteride daily and minoxidil twice daily to treat hair loss, with other users congratulating him on the significant improvement.

Federal funding cuts have delayed PP405 research, affecting hair loss treatment progress, though clinical trials will continue. The discussion highlights PP405's potential compared to minoxidil and finasteride and stresses the importance of government-funded research.

. This user experienced positive results from using a combination of minoxidil and finasteride, with no reported side effects after two months. Others have also shared their experiences with both short-term and long-term use of finasteride.

A 32-year-old is pleased with hair growth results from using oral finasteride (1.2mg) and minoxidil (3mg) without side effects, after switching from topical minoxidil. They report no shedding and increased facial hair density, and they purchase the combo pill from the Hims brand.

Pelage Pharmaceuticals' PP405 aims to treat hair loss by reactivating dormant hair follicle stem cells, showing promising results in early trials. The company plans to present their findings at the American Academy of Dermatology Annual Meeting in 2026.

The user experienced hair loss after chikungunya and started PRF (platelet-rich fibrin) injections with injectable Dutasteride, noticing new hair growth. They are hopeful for continued improvement.

The user experienced initial hair density improvement with finasteride, but later felt scalp pain and a plateau in results. They added alfatradiol for scalp inflammation and divi scalp serum to their routine, and are curious if others have similar experiences.

RU58841, a potential hair loss treatment, was not commercialized due to marketability issues and lack of long-term safety data. Concerns about its formulation and delivery methods further complicate its use.

A user is considering switching from oral to topical finasteride to reduce systemic DHT impact and is exploring ethossomal finasteride for better skin penetration and potential hair regrowth. They found ethossomal finasteride in Brazil and are seeking opinions on its effectiveness compared to other topical delivery methods.

A user is considering a 3-in-1 capsule containing Finasteride, Minoxidil, and Biotin for hair loss. Concerns are raised about Biotin's impact on the effectiveness of Finasteride and Minoxidil, and the cost is unclear without logging in.

ET-02, a PAI-1 inhibitor, is not proven to be more effective than Minoxidil for hair loss. Other treatments like finasteride, dutasteride, PP405, and AMP-303 are also discussed, focusing on cellular senescence and oxidative stress.

The discussion is about whether to continue reducing finasteride dosage with already low DHT levels. Treatments mentioned include minoxidil, finasteride, and RU58841.

Pyrilutamide is believed to be more effective than RU58841 and 1 mg finasteride in treating hair loss, with no systemic hormonal effects and the potential to block more than 31% of scalp DHT. It may also antagonize scalp testosterone due to its action as an androgen receptor antagonist.

The user experienced good hair regrowth using natural methods and mechanical stimulation but decided to add finasteride to their regimen for better results. They are optimistic about further regrowth and plan to update on the effects of finasteride, noting no significant side effects so far.

Hair loss due to DHT is causing distress, with Minoxidil, finasteride, and RU58841 being potential treatments. The conversation includes humor and frustration about the topic.

The user has been using dutasteride and finasteride but still experiences hair loss and high DHT levels. They plan to try topical finasteride and RU58841 while continuing dutasteride to see if topicals are more effective.

RU58841 and tretinoin are discussed for better absorption in hair loss treatment. The effectiveness of tretinoin with minoxidil is debated.

The conversation discusses a hair loss treatment involving oral minoxidil, topical finasteride, and a custom topical formulation with minoxidil, cetirizine, finasteride, progesterone, and hydrocortisone. The user seeks advice on the effectiveness of these ingredients for diffuse thinning.

The conversation discusses the potential of a new hair loss drug, CB-03-01, with users sharing their experiences and seeking advice on dosages and application methods. One user mentions using topical finasteride, minoxidil, dermarolling, and a clean diet for hair maintenance but is interested in CB-03-01 due to side effects from finasteride.

Using a combination of low-dose topical finasteride (0.025%) and 0.5% pyrilutamide for hair loss, with a focus on minimizing side effects. The user seeks experiences and results from others who have tried this combination.

OP experienced diffuse thinning for 11 years and used Minoxidil and Finasteride previously. They now use Pyrilutamide 0.5% and Alfatradiol 0.1%, resulting in significantly reduced hair loss.

People are discussing the potential of a new hair loss treatment, pp405, and its approval timeline, comparing it to existing treatments like Minoxidil and finasteride. There is skepticism about its effectiveness and concerns about the time it will take for approval and availability, especially in Europe.

The conversation discusses hair regrowth using 2-deoxy-d-ribose (2DDR) combined with minoxidil, with some users noting new hair growth. The original poster has been using minoxidil for 12 years and is considering combining 2DDR with finasteride, despite past side effects.

A user is concerned about hair loss in the temple area despite using Minoxidil and finasteride for 10 months and is curious if PP405 can help. Responses indicate uncertainty about PP405's effectiveness, with some optimism about future treatments and AI speeding up drug discovery, but emphasize waiting for clinical trial results.

Kintor Pharmaceutical's Phase 2 results with the drug Pyrilutamide, a potential alternative to 5-ARI drugs like Finasteride and Dutasteride but without the side effects. It could be used in combination with other topical treatments such as Minoxidil. The safety of the drug has been demonstrated in 6 months of use, however there are still questions about long term efficacy and systemic absorption.

The user has been taking 1mg of finasteride daily for a year, maintaining hair density without regrowth. They are considering oral minoxidil for regrowth, avoiding topical minoxidil due to its toxicity to cats, despite concerns about heart side effects.

VDPHL-01 is essentially a slow-release oral minoxidil, which is already known to work for hair growth. The formulation includes other ingredients like Medrogestone, Valproic acid, Setipiprant, and Cetirizine, but their effectiveness and necessity are questioned.

The user is pleased with their hair transplant results after six months and seeks feedback. The conversation is positive, with others affirming the success of the procedure.

The conversation discusses hair regrowth using finasteride, minoxidil, biotin, and vitamin D over three months, with visible results. One person asks about the daily dosage of vitamin D and biotin.

A user shared their 9-month progress using RU58841 at 2% daily for hair regrowth, initially starting at 5% but reducing the dose due to early signs of gynecomastia, which has since mostly resolved. They achieved their goal of regrowing hair at the temples and hairline.